Yayın:
Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

Sadeleştirilmiş öğe sayfası
dc.contributor.authorTurhal, N. S.
dc.contributor.authorÜskent, Necdet
dc.contributor.authorAbdullah Sakin
dc.contributor.authorSemiha Urvay
dc.contributor.authorAtike Gökçen Demiray
dc.contributor.authorSüleyman Şahin
dc.contributor.authorTeoman Şakalar
dc.contributor.authorCihan Erol
dc.contributor.authorMehmet Alı Nahıt Şendur
dc.contributor.authorAhmet Bilgehan Şahin
dc.contributor.authorErdem Çubukçu
dc.contributor.authorDeniz Can Güven
dc.contributor.authorSaadettin Kılıçkap
dc.contributor.authorYakup Ergün
dc.contributor.authorDoğan Uncu
dc.contributor.authorN. S. Turhal
dc.contributor.authorNecdet Üskent
dc.contributor.authorHavva Yeşil Çınkır
dc.contributor.authorAtakan Demir
dc.contributor.authorRamazan Acar
dc.contributor.authorNuri Karadurmuş
dc.contributor.authorSema Türker
dc.contributor.authorMustafa Altınbaş
dc.contributor.authorMert Karaoğlan
dc.contributor.authorFiliz Çay Şenler
dc.contributor.orcid0000-0001-7680-4142
dc.contributor.orcid0000-0002-7531-7817
dc.contributor.orcid0000-0003-2538-8569
dc.contributor.orcid0000-0002-0181-3842
dc.contributor.orcid0000-0003-4397-5468
dc.contributor.orcid0000-0001-9769-2565
dc.contributor.orcid0000-0003-2749-9414
dc.contributor.orcid0000-0003-3155-8798
dc.contributor.orcid0000-0001-7021-6139
dc.contributor.orcid0000-0002-7846-0870
dc.contributor.orcid0000-0002-0070-0889
dc.contributor.orcid0000-0002-6924-9467
dc.contributor.orcid0000-0003-1637-7390
dc.contributor.orcid0000-0003-4784-6743
dc.contributor.orcid0000-0002-0929-3271
dc.contributor.orcid0000-0002-1013-5676
dc.contributor.orcid0000-0003-2739-7362
dc.contributor.orcid0000-0002-7870-8741
dc.contributor.orcid0000-0002-1940-4086
dc.contributor.orcid0000-0002-3094-899X
dc.contributor.orcid0000-0003-3291-8062
dc.contributor.orcid0000-0001-9040-7266
dc.contributor.orcid0000-0002-8024-2362
dc.contributor.orcid0000-0001-5069-685X
dc.contributor.orcid0000-0002-7156-4650
dc.date.accessioned2025-11-13T11:27:55Z
dc.date.issued2021-02-04
dc.identifier.doihttps://doi.org/10.1007/s12029-021-00594-1
dc.identifier.endpage288
dc.identifier.issn1941-6628
dc.identifier.issue2
dc.identifier.openalexW3126704877
dc.identifier.startpage282
dc.identifier.urihttps://hdl.handle.net/11421/6881
dc.identifier.urihttps://doi.org/10.1007/s12029-021-00594-1
dc.identifier.volume53
dc.language.isoen
dc.relation.ispartofJournal of Gastrointestinal Cancer
dc.rightsrestrictedAccess
dc.subjectCapecitabine
dc.subjectTrastuzumab
dc.subjectMedicine
dc.subjectInternal medicine
dc.subjectOncology
dc.subjectChemotherapy
dc.subjectCancer
dc.subjectCardiotoxicity
dc.subjectBreast cancer
dc.subjectColorectal cancer
dc.subject.sdg3
dc.titleTrastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5064011743
local.authorid.openalexA5064757657

Dosyalar

Koleksiyonlar

Publications